Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting
Aldeyra Therapeutics (ALDX) has announced its participation in the Disruptive Innovations Symposium at the OSN New York Retina 2024 Meeting, scheduled for November 8-10, 2024. Dr. Tomasz Stryjewski, Chief Medical Advisor - Retina, will present on the Phase 2/3 clinical development of ADX-2191 for retinitis pigmentosa treatment on November 8, 2024, from 3:30-5:30 p.m. ET.
The company specializes in developing therapies for immune-mediated and metabolic diseases, focusing on RASP modulators including ADX-629, ADX-248, ADX-743, and ADX-631. Their late-stage candidates include reproxalap for dry eye disease and allergic conjunctivitis, and ADX-2191, an intravitreal methotrexate formulation for retinitis pigmentosa.
Aldeyra Therapeutics (ALDX) ha annunciato la sua partecipazione al Simposio sulle Innovazioni Disruptive durante l'incontro OSN New York Retina 2024, previsto per il 8-10 novembre 2024. Il Dr. Tomasz Stryjewski, Chief Medical Advisor - Retina, presenterà lo sviluppo clinico di Fase 2/3 di ADX-2191 per il trattamento della retinite pigmentosa l'8 novembre 2024, dalle 15:30 alle 17:30 ET.
L'azienda si specializza nello sviluppo di terapie per malattie mediate dal sistema immunitario e metaboliche, concentrandosi sui modulatori RASP tra cui ADX-629, ADX-248, ADX-743 e ADX-631. I loro candidati in fase avanzata includono reproxalap per la malattia dell'occhio secco e la congiuntivite allergica, e ADX-2191, una formulazione di metotrexato intravitreale per la retinite pigmentosa.
Aldeyra Therapeutics (ALDX) ha anunciado su participación en el Simposio de Innovaciones Disruptivas en la reunión OSN New York Retina 2024, programada del 8 al 10 de noviembre de 2024. El Dr. Tomasz Stryjewski, Asesor Médico Jefe - Retina, presentará el desarrollo clínico de Fase 2/3 de ADX-2191 para el tratamiento de la retinitis pigmentosa el 8 de noviembre de 2024, de 3:30 a 5:30 p.m. ET.
La empresa se especializa en el desarrollo de terapias para enfermedades mediadas por el sistema inmunológico y metabólicas, centrándose en los moduladores de RASP, incluidos ADX-629, ADX-248, ADX-743 y ADX-631. Sus candidatos en etapa avanzada incluyen reproxalap para la enfermedad ocular seca y la conjuntivitis alérgica, y ADX-2191, una formulación de metotrexato intravítreo para la retinitis pigmentosa.
알데이라 테라퓨틱스 (ALDX)가 2024년 11월 8일부터 10일까지 예정된 OSN 뉴욕 망막 회의에서 파괴적 혁신 심포지엄에 참여한다고 발표했습니다. 알렉산더 스트리예프스키 박사, 망막 분야 수석 의료 자문이 2024년 11월 8일 오후 3시 30분부터 5시 30분(ET)까지 ADX-2191의 망막색소변성증 치료를 위한 2/3상 임상 개발에 대해 발표할 예정입니다.
회사는 면역 매개 및 대사 질환에 대한 치료제를 개발하는 데 전문화되어 있으며, ADX-629, ADX-248, ADX-743 및 ADX-631과 같은 RASP 조절제에 주력하고 있습니다. 그들의 후기 후보는 건성안 및 알레르기 결막염에 대한 reproxalap과 망막색소변성증에 대한 안구내 메토트렉세이트 제형인 ADX-2191을 포함합니다.
Aldeyra Therapeutics (ALDX) a annoncé sa participation au Symposium sur les Innovations Disruptives lors de la Réunion OSN New York Retina 2024, prévue du 8 au 10 novembre 2024. Dr. Tomasz Stryjewski, Chief Medical Advisor - Retina, présentera le développement clinique de Phase 2/3 de ADX-2191 pour le traitement de la rétinite pigmentaire le 8 novembre 2024, de 15h30 à 17h30 ET.
L'entreprise se spécialise dans le développement de thérapies pour les maladies médiées par le système immunitaire et métaboliques, se concentrant sur les modulateurs RASP, y compris ADX-629, ADX-248, ADX-743 et ADX-631. Leurs candidats en phase avancée comprennent reproxalap pour la sécheresse oculaire et la conjonctivite allergique, ainsi qu'ADX-2191, une formulation intravitréenne de méthotrexate pour la rétinite pigmentaire.
Aldeyra Therapeutics (ALDX) hat seine Teilnahme am Symposium für disruptive Innovationen während der OSN New York Retina 2024 Sitzung angekündigt, die vom 8. bis 10. November 2024 stattfinden wird. Dr. Tomasz Stryjewski, Chief Medical Advisor - Retina, wird am 8. November 2024 von 15:30 bis 17:30 Uhr ET über die klinische Entwicklung der Phase 2/3 von ADX-2191 zur Behandlung der Retinitis pigmentosa berichten.
Das Unternehmen ist auf die Entwicklung von Therapien für immunvermittelte und metabolische Erkrankungen spezialisiert und konzentriert sich auf RASP-Modulatoren, einschließlich ADX-629, ADX-248, ADX-743 und ADX-631. Zu ihren spätphasigen Kandidaten gehören reproxalap für trockene Augen und allergische Konjunktivitis sowie ADX-2191, eine intravitrealen Methotrexat-Formulierung für Retinitis pigmentosa.
- None.
- None.
Dr. Stryjewski will provide an overview of the Phase 2/3 clinical development of ADX-2191 in retinitis pigmentosa. The session will run from 3:30 – 5:30 p.m. ET on Friday, November 8, 2024.
About Aldeyra
Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated and metabolic diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX-629, ADX-248, ADX-743, ADX-631, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Our late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241031692801/en/
Investor & Media Contact:
Laura
Tel: (781) 257-3060
investorrelations@aldeyra.com
Source: Aldeyra Therapeutics, Inc.
FAQ
When will Aldeyra (ALDX) present at the OSN New York Retina 2024 Meeting?
What will be the focus of Aldeyra's (ALDX) presentation at the OSN New York Retina 2024 Meeting?
What are Aldeyra's (ALDX) main late-stage product candidates?
Which RASP modulators is Aldeyra (ALDX) currently developing?
